SNORD116 and growth hormone therapy impact IGFBP7 in Prader-Willi syndrome.

Sanaa EddiryGwenaelle DieneCatherine MolinasJuliette SallesFrançoise Conte AuriolIsabelle GenneroEric BiethBoris V SkryabinTimofey S RozhdestvenskyLisa C BurnettRudolph L LeibelMaithé TauberJean Pierre Salles

Published in: Genetics in medicine : official journal of the American College of Medical Genetics (2021)

SNORD116 deletion affects IGFBP7 levels, while IGFBP7 decreases under GHT in PWS patients. Modulation of the IGFBP7 level, which interacts with IGF1, has implications in the pathophysiology and management of PWS under GHT.

Keyphrases

growth hormone
end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
stem cells
binding protein
case report
cell proliferation
bone marrow
patient reported outcomes